Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone
- 1 January 1992
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 118 (1) , 44-49
- https://doi.org/10.1007/bf01192310
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Grwoth Inhibition of Mouse MXT Mammary Tumor by the Luteinizing Hormone-Releasing Hormone Antagonist SB-75JNCI Journal of the National Cancer Institute, 1990
- LHRH analogues in the treatment of cancerCancer Treatment Reviews, 1989
- New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analoguesInternational Journal of Peptide and Protein Research, 1988
- Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.Proceedings of the National Academy of Sciences, 1988
- Reproductive/endocrine and anaphylactoid properties of an LHRH-antagonist, ORF 18260 [Ac-DNAL1(2),4FDPhe2,D-Trp3,D-Arg6]-GnRHLife Sciences, 1985
- [Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in ratsContraception, 1984
- Long-Term Treatment of Central Precocious Puberty with a Long-Acting Analogue of Luteinizing Hormone-Releasing HormoneNew England Journal of Medicine, 1983
- Elevated blood pressure following LHRH antagonists in ratsContraception, 1982
- Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan*Deutsche Medizinische Wochenschrift (1946), 1963
- Mammary Cancer Induced by a Single Feeding of Polynuclear Hydrocarbons, and its SuppressionNature, 1961